These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15980987)

  • 1. Breast cancer predisposing alleles in Poland.
    Górski B; Cybulski C; Huzarski T; Byrski T; Gronwald J; Jakubowska A; Stawicka M; Gozdecka-Grodecka S; Szwiec M; Urbański K; Mituś J; Marczyk E; Dziuba J; Wandzel P; Surdyka D; Haus O; Janiszewska H; Debniak T; Tołoczko-Grabarek A; Medrek K; Masojć B; Mierzejewski M; Kowalska E; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2005 Jul; 92(1):19-24. PubMed ID: 15980987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
    Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
    Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
    Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
    Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHEK2-positive breast cancers in young Polish women.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubinski J
    Clin Cancer Res; 2006 Aug; 12(16):4832-5. PubMed ID: 16914568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
    Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
    Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
    Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
    Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline NBS1 mutations in families with aggregation of Breast and/or ovarian cancer from north-east Poland.
    Kanka C; Brozek I; Skalska B; Siemiatkowska A; Limon J
    Anticancer Res; 2007; 27(4C):3015-8. PubMed ID: 17695489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
    Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
    J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovering moderate-risk breast cancer susceptibility genes.
    Hollestelle A; Wasielewski M; Martens JW; Schutte M
    Curr Opin Genet Dev; 2010 Jun; 20(3):268-76. PubMed ID: 20346647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.
    Cybulski C; Huzarski T; Byrski T; Gronwald J; Debniak T; Jakubowska A; Górski B; Wokołorczyk D; Masojć B; Narod SA; Lubiński J
    Clin Genet; 2009 Jan; 75(1):72-8. PubMed ID: 19021634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
    Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
    Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
    Elsakov P; Kurtinaitis J; Petraitis S; Ostapenko V; Razumas M; Razumas T; Meskauskas R; Petrulis K; Luksite A; Lubiński J; Górski B; Narod SA; Gronwald J
    Clin Genet; 2010 Oct; 78(4):373-6. PubMed ID: 20345474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009].
    Blecharz P; Szatkowski W; Klimek M; Urbański K
    Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
    Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 mutations and prostate cancer in Poland.
    Cybulski C; Górski B; Gronwald J; Huzarski T; Byrski T; Debniak T; Jakubowska A; Wokołorczyk D; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Romuald Z; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Posmyk M; Narod SA; Lubiński J
    Eur J Cancer Prev; 2008 Feb; 17(1):62-6. PubMed ID: 18090912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.